FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Status:
Recruiting
Trial end date:
2039-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose-finding study of FT596 as monotherapy and in combination with
Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic
Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion
stage where participants will be enrolled into indication-specific cohorts.